Dermata Therapeutics (DRMA) Projected to Post Quarterly Earnings on Monday

Dermata Therapeutics (NASDAQ:DRMA) is projected to issue its results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of ($1.54) per share for the quarter.

Dermata Therapeutics Stock Down 4.0%

NASDAQ:DRMA opened at $1.19 on Friday. The stock has a market cap of $3.38 million, a price-to-earnings ratio of -0.15 and a beta of 0.60. The company’s 50 day moving average price is $1.77 and its 200-day moving average price is $3.11. Dermata Therapeutics has a 52 week low of $1.11 and a 52 week high of $23.70.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Dermata Therapeutics in a research report on Monday, December 29th. Wall Street Zen raised Dermata Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.00.

Hedge Funds Weigh In On Dermata Therapeutics

A hedge fund recently bought a new stake in Dermata Therapeutics stock. Clear Street Group Inc. purchased a new position in Dermata Therapeutics, Inc. (NASDAQ:DRMA) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 17,000 shares of the company’s stock, valued at approximately $39,000. Clear Street Group Inc. owned about 0.60% of Dermata Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 8.67% of the company’s stock.

Dermata Therapeutics Company Profile

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.